# A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy

> **NCT04302441** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 550 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Vinorelbine
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT04302441
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11-10
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-06-30
- **Target enrollment:** 550 (ESTIMATED)
- **Last updated:** 2020-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04302441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04302441, "A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04302441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*